This is a single center exploratory imaging study involving one intravenous microdose of
[18F]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR)
imaging in HIV infected individuals to determine the anatomical distribution of the PET
tracer. Participants will be enrolled if they were treated during early or late HIV
infection. In addition, individuals not on antiretroviral therapy (ART) or with HIV-1 plasma
RNA levels >5,000 copies/mL will be enrolled.
Phase:
Phase 1
Details
Lead Sponsor:
CellSight Technologies, Inc.
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) University of California, San Francisco